Clinical trials: Cholangiocarcinoma Resectable
Liver Cancer
SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00020774
- Testing
- gemcitabine hydrochloride, lonafarnib, conventional surgery
- Sponsor
- Jonsson Comprehensive Cancer Center
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
This phase II trial assesses the feasibility (including both safety and tolerability) of conducting Next Generation Sequencing and administering targeted therapy (infigratinib) in the preoperative setting for patients with…
- Conditions
- Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT05514912
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Infigratinib Phosphate
- Sponsor
- Emory University
Cholangiocarcinoma Non-resectable
Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for…
- Trial name
- CCGLC-013 (NCT06192797)
- Testing
- HAIC, Lenvatinib plus pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Intrahepatic Cholangiocarcinoma
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Clinical Study on the efficacy and safety of HAIC（GEMOX）and Lenvatinib combined with Adebrelimab neoadjuvant therapy for resectable Intrahepatic Cholangiocarcinoma with high-risk recurrence factors.
- Trial name
- NCT06208462
- Testing
- Adebrelimab, Lenvatinib, Gemcitabine
- Where
- 3 sites in China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Choledocholithiasis, Choledocholithiasis With Acute Cholangitis
Spanish Registry of Quality Indicators and Adverse Events of Endoscopic Retrograde Cholangiopancreatography
Endoscopic retrograde cholangiopancreatography (ERCP) is a technique which combines endoscopic and radiological vision and allows for therapeutic procedures on pathologies of the pancreas and bile duct.
- Conditions
- Choledocholithiasis, Choledocholithiasis With Acute Cholangitis, Cholangiocarcinoma, Sclerosing Cholangitis
- Trial name
- NCT06670547
- Testing
- Endoscopic retrograde cholangiopancreatography (ERCP)
- Volunteers
- 3,000 people
- Sponsor
- Germans Trias i Pujol Hospital
Cholangiocarcinoma, Biliary Tract Cancer (BTC)
Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
To investigate the efficacy and tolerability of neoadjuvant tislelizumab, gemcitabine, cisplatin and S-1 (TisGCS) in patients with resectable high-risk iCCA.
- Trial name
- TisGCS for BTC (NCT06903273)
- Testing
- Tislelizumab
- Where
- Taiwan
- Volunteers
- 35 people
- Sponsor
- National Cheng-Kung University Hospital
BTC
Iparomlimab and Tuvonralimab Injection Combined With GemOX and Lenvatinib as Conversion Therapy for Initially Potentially Resectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
The primary objective is to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706, an Anti-PD-1/CTLA-4 Combined Antibody) combined with GemOX and lenvatinib as conversion therapy for Initially…
- Trial name
- NCT07263360
- Testing
- Iparomlimab and Tuvonralimab Injection combined with GemOX and lenvatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cholangiocarcinoma, Cholangiocarcinoma Non-resectable
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma
ABC-108 is a single-arm Phase IIA clinical study of ABC294640 (Yeliva ®, opaganib) alone and in combination with hydroxychloroquine sulfate (HCQ) in the treatment of cholangiocarcinoma (CCA).
- Conditions
- Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT03377179
- Testing
- ABC294640, Hydroxychloroquine Sulfate 200 MG
- Where
- 5 sites in United States
- Volunteers
- 65 people
- Sponsor
- RedHill Biopharma Limited
Biliary Tract Cancer, Cholangiocarcinoma
Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer
The NEOBIL study aims to investigate the feasibility, safety and efficacy of neoadjuvant Bintrafusp alfa in patients with resectable biliary tract cancer.
- Trial name
- NEOBIL (NCT04727541)
- Testing
- Bintrafusp alfa
- Where
- 2 sites in Germany
- Volunteers
- 3 people
- Sponsor
- AIO-Studien-gGmbH
Hilar Cholangiocarcinoma
Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy
Bile duct cancer is often diagnosed after curative options are no longer available. Stent therapy is used to keep the ducts open and can be combined with photodynamic therapy (PDT) to extend life expectancy.
- Trial name
- CARP (NCT05551299)
- Testing
- Photosensitizer, Radiofrequency ablation (RFA)
- Where
- 20 sites in Germany
- Volunteers
- 258 people
- Sponsor
- University of Leipzig
Intrahepatic Cholangiocarcinoma
LIver Transplantation for Non-Resectable Intrahepatic CholAngiocarcinoma (LIRICA)
LIRICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable iCCA after a downstaging/disease control protocol with standard of care chemotherapy, in…
- Trial name
- LIRICA (NCT06098547)
- Testing
- Liver transplantation
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Azienda Sanitaria Ospedaliera
Intrahepatic Cholangiocarcinoma
Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC
The goal of this clinical trial is to explore the efficacy and safety of combined infusion chemotherapy with Adebrelimab and Apatinib in the perioperative treatment of resectable intrahepatic cholangiocarcinoma patients.
- Trial name
- NCT06296563
- Testing
- HAIC, Adebrelimab, Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei ZHAO
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery
This phase II trial is studying how well MD2206 works in treating patients with advanced refractory biliary cancer that cannot be removed by surgery.
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma
- Trial name
- NCT01425879
- Testing
- Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Perihilar Cholangiocarcinoma
LIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
LITALHICA is a prospective non-randomized study aimed at exploring the outcome of liver transplantation in selected patients with unresectable perihilar cholangiocarcinoma (pCCA) after treatment with standard of care…
- Trial name
- LITALHICA (NCT06125769)
- Testing
- Liver transplantation
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Azienda Sanitaria Ospedaliera
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Resectable Intrahepatic Cholangiocarcinoma
Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
Treatment of intrahepatic cholangiocarcinoma (ICC) remains difficult. Many patients have unresectable tumors, and survival after resection was only slightly improved with the use of adjuvant capecitabine.
- Trial name
- SIROCHO (NCT05265208)
- Testing
- Capecitabine, Selective Internal Radiotherapy (SIRT), Surgery
- Where
- 7 sites in France
- Volunteers
- 62 people
- Sponsor
- Center Eugene Marquis
Intrahepatic Cholangiocarcinoma, PD1 Antibody
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low…
- Conditions
- Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib, Gemox Chemotherapy
- Trial name
- NCT04669496
- Testing
- Neoadjuvant treatment
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Cholangiocarcinoma, Intrahepatic
PD1 Antibody (Toripalimab), GEMOX and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
A randomized controlled, multi-center, open, phase II clinical study is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative…
- Trial name
- NCT04506281
- Testing
- neoadjuvant treatment
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Shanghai Zhongshan Hospital
Cholangiocarcinoma Non-resectable
Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of drug eluting beads-transcatheter arterial chemoembolization combined with lenvatinib and pucotenlimab as…
- Trial name
- CCGLC-012 (NCT06192784)
- Testing
- DEB-TACE, Lenvatinib plus pucotenlimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital